# A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT02807558** · PHASE2 · COMPLETED · sponsor: **Syros Pharmaceuticals** · enrollment: 155 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Tamibarotene
- **DRUG:** Azacitidine
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT02807558
- **Lead sponsor:** Syros Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-01-25
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02807558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02807558, "A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02807558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*